Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test Used in DIRECT Study to Investigate the T Cell Response and COVID Vacci...
April 29 2021 - 9:15AM
Oxford Immunotec a global, high-growth diagnostics company part of
PerkinElmer (NYSE: PKI), today announced that its
T-SPOT
® Discovery SARS-CoV-2 kit will be used for
T cell testing in the DIRECT study. Oxford Immunotec is
collaborating with researchers at the University of Leicester on
DIRECT (Determining the Immune Response in Ethnic minority
healthcare workers to COVID-19 infection). The study, funded
through the National Core Studies group, is actively recruiting
healthcare workers in Leicester for detailed analysis of their
immune response to infection and / or vaccination (including T
cells). This analysis, together with information collected through
online questionnaires, will enable researchers to understand
whether there are differences in the immune response in different
ethnic minority groups, including whether there are differences in
the magnitude and duration of this response.
The custom version of the T-SPOT Discovery
SARS-CoV-2 kit (for research use only) will be used to assess if
the vaccination induces a T cell response in study subjects. The
kit uses the T-SPOT technology platform, a commercialized, modified
ELISPOT platform, which allows for the standardized and
reproducible measurement of T cells reactive to SARS-CoV-2. Testing
for an immune response using T cells may offer several advantages
over conventional antibody testing due to the limitations reported
with antibodies, such as antibodies not being present after
infection and antibodies waning over time. The T-SPOT Discovery
SARS-CoV-2 test has also demonstrated in previous studies that a
high SARS-CoV-2 specific T cell response may be associated with
protection from infection.
Dr. Peter Wrighton-Smith, CEO of Oxford
Immunotec said, “We are proud to be partnering with the University
of Leicester on this critical clinical trial which will help drive
the understanding of the effects of COVID-19 across different
ethnic groups.”
Dr Manish Pareek, Principal Investigator of
DIRECT said, “The immune system is critical to the outcome of
COVID-19, including protection against future infection. This
study, utilizing a wide range of immune measures including the
T-SPOT technology developed by Oxford Immunotec, will allow us to
determine differences in the immune response to COVID-19 amongst
different ethnic minority groups, which is vital if we are to
understand why individuals from ethnic minority groups are
disproportionately affected by COVID-19.”
Find out more about DIRECT at https://direct.uk-reach.org/
For further information visit: www.tspotdiscovery.com
T-SPOT Discovery SARS-CoV-2 is for
research use only, not for use in diagnostic
procedures.
About Oxford
ImmunotecOxford Immunotec is a global, high-growth
diagnostics company and part of the PerkinElmer group. We bring
energy and invention to a world in need of diagnostic truth. We are
uniquely placed as the only company in the world offering regulated
ELISPOT assays for T cell measurement, with approval around the
globe. Our leading product, the T-SPOT.TB test, is used for
diagnosing infection with Tuberculosis, the world’s largest cause
of death from infectious disease. The Company is an experienced
manufacturer of IVD tests, operating under a fully audited Quality
Management System, ensuring rigorous batch control. The company has
manufactured in excess of 20 million clinical T cell tests for TB
infection. The T-SPOT.TB test has been approved for sale in over 50
countries, including the United States (where it has received
pre-market approval from the Food and Drug Administration), Europe
(where it has obtained a CE mark), as well as Japan and China. The
recently released T-SPOT.COVID test is CE marked in Europe for
clinical use to understand the T cell immune response to SARS-CoV-2
infection and has been submitted to the FDA for emergency use
authorization in the US (www.tspotcovid.com). The Company is
headquartered near Oxford, U.K. and in Marlborough, MA. Additional
information can be found at www.oxfordimmunotec.com.
About PerkinElmerPerkinElmer
enables scientists, researchers and clinicians to address their
most critical challenges across science and healthcare. With a
mission focused on innovating for a healthier world, we deliver
unique solutions to serve the diagnostics, life sciences, food and
applied markets. We strategically partner with customers to enable
earlier and more accurate insights supported by deep market
knowledge and technical expertise. Our dedicated team of about
14,000 employees worldwide is passionate about helping customers
work to create healthier families, improve the quality of life, and
sustain the wellbeing and longevity of people globally. The Company
reported revenue of approximately $3.8 billion in 2020, serves
customers in 190 countries, and is a component of the S&P 500
index. Additional information is available through 1-877-PKI-NYSE,
or at www.perkinelmer.com.
For Media Inquiries:
US: Mary ConwayMKC Strategies, LLCTel: +1 (516)
606-6545 MConway@MKCStrategies.com
UK: Megan AndersonZPB AssociatesMobile:
07597572287Office: (020) 7018
1124megan.anderson@zpb-associates.com
PerkinElmer (NYSE:PKI)
Historical Stock Chart
From Mar 2024 to Apr 2024
PerkinElmer (NYSE:PKI)
Historical Stock Chart
From Apr 2023 to Apr 2024